Abstract. Metastasis is the most common cause of death in ovarian cancer patients but remains largely untreated. Epithelial-mesenchymal transition (EMT) is critical for the conversion of early-stage ovarian tumors into metastatic malignancies. Thus, investigating the signaling pathways promoting EMT may identify potential targets for the treatment of metastatic ovarian cancer. Lysine demethylase 2A (KDM2A), also known as FBXL11 and JHDM1A, is a histone H3 lysine 36 (H3K36) demethylase that regulates EMT and the metastasis of ovarian cancer. However, the function and underlying mechanisms of EMT suppression in ovarian cancer have not been thoroughly elucidated to date. In the present study, we used Gene Expression Omnibus (GEO) databases to determine that KDM2A is significantly upregulated in human ovarian cancers. KDM2A expression was assessed by immunohistochemistry of epithelial ovarian cancer (EOC) borderline ovarian tumors and normal ovary tissues. Seven fresh EOC tissues and 3 fresh normal ovary tissues were collected for western blot analysis. Kaplan-Meier survival curves were constructed to identify genes related to EOC prognosis from the TCGA data portal. Stable KDM2A-knockdown cell lines were established to study the biological functions and underlying mechanisms of KDM2A in EMT in vitro. GEO database analysis revealed that KDM2A was highly upregulated in EOC tissues; this analysis was accompanied by immunochemistry and western blot analysis using samples of human tissues. High expression of KDM2A was associated with poor survival in EOC patients. KDM2A knockdown promoted apoptosis and suppressed the proliferation, migration and invasion of tumor cells in vitro. EMT and the PI3K/AKT/mTOR signaling pathway were suppressed in KDM2A-silenced cells. Inactivation of the PI3K/AKT/mTOR signaling pathway in A2780 cells induced EMT inhibition. Our data revealed that KDM2A functions as a tumor oncogene, and the downregulation of KDM2A expression regulates EMT and EOC progression, providing a valuable prognostic marker and potential target for the treatment of EOC patients.
Introduction
Ovarian cancer is the second most common gynecological cancer and currently ranks as one of the leading causes of cancer-related deaths among women worldwide (1, 2) . Epithelial ovarian cancer (EOC) is the most common and lethal type of the disease, which accounts for approximately 85-95% of all ovarian cancer cases. EOC treatment commonly results in a low response rate to surgical resection, radiotherapy, chemotherapy and poor prognosis with a median survival of <5 years in approximately 30% of patients (3, 4) . The high morbidity and mortality rates are contributed to the fact that patients may appear asymptomatic in the early stages; therefore, 70-75% of patients in the advanced stages are often diagnosed after the cancer has circulated throughout the abdominal cavity (5, 6) . Therefore, a rapidly expanding understanding of the molecular mechanisms underlying the pathogenesis of EOC, especially the mechanisms that affect OC cell invasive, has the potential to strongly influence treatment outcomes for this devastating disease.
The histone H3 lysine 36 demethylase enzyme (KDM2A) has been previously shown to demethylate histone H3K36, contain an F-box domain, a JmjC domain, a CxxC zinc finger domain, a PHD domain and 3 leucine-rich repeat elements belonging to the KDM gene family (7) (8) (9) . KDM2A was first discovered in kidney COS-7 cells exhibiting robust histone demethylase activity (10) . KDM2A was found to be highly expressed in lung (11) , pancreatic cancer (12) , colorectal adenocarcinoma (13) , breast (14) , gastric cancer (15) and certain blood diseases (16) , which have been reported to be Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial-mesenchymal transition related to tumor aggressiveness and metastasis, chemotherapy resistance and poor prognosis. This protein has been linked to many signaling pathways, which promote cancer metastasis and malignancy. Wagner et al showed that KDM2A promoted lung tumorigenesis via the ERK1/2 signaling pathway (11).
Chen et al reported that KDM2A promoted angiogenesis and stemness by upregulating Jagged1 (17) . However, the role of KDM2A and its underlying mechanism still remain unclear in EOC proliferation, migration and metastasis. In the present study, we demonstrated that KDM2A is overexpressed in EOC and that KDM2A promoted EOC progression and induced EMT. Furthermore, KDM2A influenced the biological behaviors previously mentioned by regulating the PI3K/AKT/mTOR pathway. These findings suggest that KDM2A may serve as a potential therapeutic target for the clinical management of EOC.
Materials and methods
Bioinformatic analysis. Gene profiling data of ovarian normal surface epithelia and ovarian cancer epithelial samples were downloaded from the GEO dataset (http://www.ncbi.nlm.nih. gov/geo). GSE14407 dataset was selected for bioinformatic analysis (18) . The differential analysis was performed using R package 'limma' (19) . Differential genes obtained from GSE14407 were visualized using the R package 'pheatmap' (https://CRAN.R-project.org/package=pheatmap) and 'ggplot2' (20) . RNA sequencing data of KDM2A was achieved from the TCGA data portal (https://cancergenome.nih.gov/), containing 374 ovarian cancer samples. Corresponding clinical data were also downloaded and filtered out for useful information. Kaplan-Meier survival curves were conducted to assess the prognostic value of KDM2A using the R package 'survival' (https://CRAN.R-project.org/package=survival).
Ovarian cancer tissue samples. Human specimens were obtained between 01 January 2005 and 31 December 2011 from 27 patients, with a mean age of 46 years (range, 18-73 years), who underwent primary tumor resection at Renmin Hospital of Wuhan University (Wuhan, China). Among the 27 cases, the specimen groups consisted of EOC (n=9), borderline ovarian tumors (n=9) and normal ovary tissues (n=9). All specimens were confirmed by at least 2 pathologists. In the present study, the patients accepted no chemotherapy or radiotherapy before surgery. Before conducting our scientific investigation, consent was obtained from all the patients and the study was approved by the Ethics Committee of Wuhan University (Wuhan, China).
Immunohistochemistry. The immunohistochemical analysis of KDM2A expression in human EOC was performed as previously described (21) . The rate of KDM2A-positive cells was scored semi-quantitatively in each section.
Cell culture and reagent. 5 cells/well into 6-well plates and cultured at 37˚C overnight under standard conditions. After 50% confluence was reached, the number of cells in a well was counted using a hemocytometer. KDM2A shRNA was transfected into the cells in Opti-MEM (Invitrogen; Thermo Fisher Scientific, Inc.) at a multiplicity of infection (MOI) of 10 [MOI = transducing units per cell (TU) number/cells], according to the manufacturer's instructions. The culture medium was replaced after a 24-h incubation. A total of 48 h after transfection, the cells were observed and photographed under a fluorescence microscope. After successful transfection, the shRNA sequence was stably expressed. Untransfected cells were used as a blank control, while cells transfected with scrambled shRNA were considered as the negative control (shControl).
Cell viability assay. Cell Counting Kit-8 (CCK-8; purchased from Dojindo Laboratories, Kumamoto, Japan) was used to determine the inhibitory effect of the silencing of KDM2A on the proliferation of A2780 and SKOV3 cell lines according to the manufacturer's instructions. Cells were seeded at ~10.0x10 3 cells/well into 96-well plates with 10% FBS and cultured for 24, 48 and 72 h. Then, 10 µl of CCK-8 was added and subsequently incubated for 1 h at 37˚C. The absorbance value (OD) at 450 nm of every well was measured with a spectrophotometric plate reader. Assays were performed in triplicate on 3 independent experiments.
Colony formation assay. An appropriate number of cells were plated on a 6-well plate (500 cells/2 ml/well) and cultured in 2 ml medium with 10% FBS. Then, cells were changed every 3 days with 10% mycoplasma-free FBS for 2 weeks until the cells in the plates had formed colonies that were of substantially right size (50 cells/colony or greater). The cells were fixed with 2 ml 75% ethanol at room temperature for 15 min, and then stained with 0.5% crystal violet. The cloning efficiency was calculated by dividing the number of wells containing proliferating cells with the total number of cell-plated wells.
Flow cytometric analysis of apoptosis with PE/7-ADD staining.
For apoptosis analysis, cells were treated for 48 h. The cells were suspended with 100 µl of 1X binding buffer (0.1 mM HEPES/NaOH, 1.4 M NaCl, 25 mM CaCl 2 and pH 7.4) and stained with 5 µl of PE Annexin V and 5 µl of 7-amino-actinomycin (7-ADD) for 15 min at room temperature and then 400 µl 1X binding buffer was added to each tube (Annexin V-PE Apoptosis Detection kit; BD Pharmingen; BD Biosciences, San Diego, CA, USA). Analysis of the results was carried out by BD FACSAria (BD Biosciences, Franklin Lakes, NJ, USA). Data were quantified using FlowJo Software (FlowJo, LLC, Ashland, OR, USA).
Hoechst staining. The 3 groups of A2780 and SKOV3 cells were fixed using methanol acetic acid for 15 min and then stained with Hoechst 33342 for 5 min. Being washed twice with PBS, the cells were immediately photographed under an Olympus BX51 inverted microscope at x400 magnification (Olympus Corp., Tokyo, Japan).
Wound healing assay. Untransfected and transfected cells were seeded at 5.0x10 5 cells/well in 6-well plates and cultured routinely. After reaching 90% confluence, the cell monolayer was scratched with a sterile pipette tip. After washing 3 times with PBS for 5 min each to clear the floating cells, 1.5 ml MEM/F12 and RPMI-1640 medium supplemented with 1% FBS were added into each well. Photographs were taken by an Olympus BX51 inverted microscope at x100 magnification (Olympus Corp.) at 0, 24 and 48 h after scratching. Results were indicated as the relative width of scratch-the distance migrated relative to the original scratched distance. The experiment was conducted 3 times.
Cell invasion assay. The invasive ability of cells was measured using the Corning ® Matrigel ® Basement Membrane Matrix (cat. no. 356234; Corning Inc., Corning, NY, USA) and a 24-well Transwell chamber (Corning Inc.) according to the manufacturer's protocol. The number of cells that passed through an 8-µm polycarbonate membrane was calculated. The polycarbonate surface of each chamber was covered with 50 µl Matrigel (1:8 dilution) to create an artificial basement membrane. Cells were cultured at 37˚C in FBS-free MEM/F12 and RPMI-1640 medium for 24 h. After serum starvation, the cells were seeded at 1x10 5 cells/well in the upper Transwell chamber, which contained ~200 µl serum-free medium. The lower chamber was filled with 500 µl of the medium supplemented with 10% FBS. After an incubation of 48 h at 37˚C, the chambers were fixed at room temperature with paraformaldehyde for 30 min. Cells that had attached to the upper surface of the chambers were removed with a sterile cotton swab, and cells that adhered to the lower surface were stained with 0.1% crystal violet (Guangfu Institute of Superfine Chemical Industry, Tianjin, China) for 20 min at room temperature. The numbers of stained cells were counted using an inverted microscope (Olympus IX 70-142; Olympus Corp.) in 8 random fields. The experiment was repeated 3 times.
Western blot analysis. Cell lysates containing equal amounts of protein was subjected to 12% SDS-PAGE and then transferred to 0.45 µm Immobilon-P transfer membranes (EMD Millipore, Billerica, MA, USA) by electroblotting. Membranes were blocked at room temperature for 1 h in TBST (50 mmol/l Tris-HCL, pH 7.6, 150 mmol/l NaCl and 0.1% Tween-20) containing 5% non-fat dry milk and then incubated with primary antibody at 4˚C overnight. The membranes were then incubated with appropriate anti-rabbit secondary antibody (dilution 1:10,000; Sigma-Aldrich; Merck KGaA) for 1 h at room temperature and visualized with a chemiluminescence substrate kit (Pierce™ ECL Western Blotting Substrate; Thermo Scientific Fisher, Inc.). The intensity of the target protein bands was normalized to the loading control, GAPDH/β-actin. 
Results

KDM2A is upregulated and associated with poor survival in EOC.
Differential analysis was performed for the GSE14407 dataset. The results showed that expression of KDM2A was significantly upregulated in 12 serous ovarian cancer epithelial samples (SOCE) compared to that noted in the 12 healthy ovarian surface epithelial samples (HOSE) (Fig. 1A and B) . Differences in the immunoreactivity of KDM2A staining were observed in EOCs, borderline epithelial ovarian tumors, and normal epithelial ovary tissues, predominantly expressed in the nucleus and light cytoplasmic staining. EOCs showed strong positive staining, while borderline epithelial ovarian tumors and normal ovary tissues showed low-level expression (Fig. 1C) . Kaplan-Meier survival analysis suggested that patients with high KDM2A expression had a poor prognosis in overall survival (Fig. 1D) . In addition, the expression level of KDM2A was higher in 7 fresh EOC tissues compared with that in 3 fresh normal ovary tissues (Fig. 1E) .
Assessment of KDM2A expression after shRNA transfection.
To test the function of KDM2A in EOCs, shRNA transfection was used for KDM2A knockdown. The knockdown efficiency was assessed by western blot analysis. The results showed that the expression of KDM2A was significantly decreased after shRNA-KDM2A transfection in human ovarian cancer cell lines SKOV3 and A2780 ( Fig. 2A and B) .
Silencing of KDM2A reduces proliferation and delays G2 phase progression. We found that KDM2A inhibition in A2780 and SKOV3 cells prevented proliferation. We tested our hypothesis to confirm whether cell viability and the colony-forming capabilities were determined by cell proliferation. As shown in Fig. 2C , CCK-8 was used to measure the viability of EOC cells transfected with sh-KDM2A. The viability of the sh-KDM2A cells was significantly lower than that for cells transfected with the sh-Control and the control group. The colony formation assay indicated that the colony-forming capabilities of the SKOV3 and A2780 cells were significantly impaired due to KDM2A depletion (Fig. 2D) . To explore whether the effects of KDM2A depletion on cell behaviors were related to cell cycle distribution, we performed flow cytometric analysis. The evidence showed that the cell cycle was related to the proliferative capabilities of cells; therefore, the effect of KDM2A in EOC was further investigated. The percentage of G2/M phase cells was increased after silencing of KDM2A (Fig. 2E and F) .
These results demonstrated cell cycle arrest in the G2/M transition due to KDM2A knockdown.
Downregulation of KDM2A stimulates cell apoptosis.
Flow cytometric analysis with PE/7-ADD staining showed that the early apoptotic cell population in the sh-KDM2A group was higher than that in the other 2 groups in the 2 cell lines (Fig. 3A and B) . Moreover, western blot analysis showed that the expression level of Bcl-2 was downregulated, while the expression level of Bax was upregulated in the same conditions (Fig. 3C) . Hoechst 33342 staining showed that the sh-KDM2A group had a greater number of apoptotic cells compared to the number of apoptotic cells in the 2 control groups (Fig. 3D) . Additionally, cells of the sh-KDM2A group showed marked morphological changes in the nuclear size than cells of the control groups.
Inhibition of KDM2A attenuates tumor migration and invasion in vitro.
The serum-stimulated Matrigel invasion assay demonstrated that the percentages of human ovarian cancer cells that migrated through the polycarbonate membrane in the sh-KDM2A transfection group were significantly lower than those in the control groups ( Fig. 4A and B) . Therefore, downregulation of KDM2A decreased cell invasion of the human ovarian cancer cell lines after transfection.
The monolayer wound healing assay was used to assess cell migration. The transfected cells showed a significant deceleration in closure of the wound scratch width after 24 and 48 h compared with the sh-Control and control groups (Fig. 4C and D) . To study the effect of KDM2A depletion on cellular response, the expression of MMP2 and MMP9 were measured in SKOV3 and A2780 cell lines. As shown in Fig. 4E , the 2 transfected proteins, showed decreased expression in the sh-KDM2A group compared to the negative control and the control group.
KDM2A promotes epithelial-mesenchymal transition (EMT)
via the PI3K/AKT/mTOR signaling pathway using the LY294002 in EOC cells. Since EMT has been increasingly recognized as a crucial event in cancer metastasis, we measured the expression of EMT markers and EMT transcription factors before/after KDM2A knockdown by western blotting. The expression level of E-cadherin was markedly upregulated, while those of N-cadherin and vimentin were significantly decreased in A2780 sh-KDM2A and SKOV3 sh-KDM2A cells compared with the sh-Control and the control cells (Fig. 5A) .
To elucidate the molecular mechanism involved in KDM2A-mediated EMT in EOC cells, we analyzed the key components of the PI3K/AKT/mTOR signaling pathway. Western blot analysis showed that KDM2A knockdown decreased the expression of phospho (p)-PI3K, p-AKT and p-mTOR compared to the control groups (Fig. 5B) . Using the PI3K signaling pathway inhibitor, LY294002 (0, 5, 10 and 20 µmol/l), we treated the A2780 and SKOV3 cells for 48 h. The results showed that inactivation of the PI3K signaling pathway led to suppression of EMT in a dose-dependent manner, while the expression level of KDM2A was not significantly changed (Fig. 5C) . The migration ability of SKOV3 and A2780 cells gradually decreased with 10 µmol/l LY294002 (Fig. 5D ). In addition, LY294002 inhibited the colony formation of SKOV3 and A2780 cells. Fewer colonies were formed in the treated group compared with the control group (Fig. 5E ). 
Discussion
In the present study, our results indicated the critical roles of KDM2A in epithelial ovarian cancer (EOC). The significant increase of KDM2A expression in EOC was determined by the GEO database. Similarly, immunohistochemical analysis and western blot analysis confirmed the overexpression of KDM2A in EOC patients compared with the borderline ovarian tumor and normal ovary tissues. Moreover, the Kaplan-Meier estimate showed that KDM2A expression was negatively associated with patient survival, indicating that higher KDM2A expression was correlated with lower overall survival rates of patients with EOC.
To further examine the role of KDM2A in EOC, we investigated the effect of KDM2A on the viability of EOC cells in vitro. The results showed that knockdown of KDM2A expression in EOC cells significantly decreased cell proliferation and efficiency of colony formation. In agreement with our findings, KDM2A functions as an oncogene in several types of cancer and several cancer cell lines possess high-level expression of KDM2A (23) . Many researchers have concluded that KDM2A may be a promising target in anticancer therapeutics. Huang et al showed that forced expression of KDM2A increased the growth and motility of gastric cancer cells by downregulating PDCD, a known tumor suppressor (24) . Kong et al reported that miR-29b and KDM2A are involved in the proliferation and metastasis of gastric cancer cells (15) . Consistent with this finding, KDM2A showed a similar effect on cell apoptosis in this study. We showed that downregulation of KDM2A decreased cell migration and invasion in vitro, suggesting that KDM2A promotes EOC tumor metastasis. Hematogenous intravasation and extravasation are less accepted as a mechanism of EOC metastasis. Instead, when cells reach a threshold value, limited by epithelial-mesenchymal transition (EMT) or EMT-like events and growth, a primary OC would passively shed cells from their original location, leading to spheroid formation and formation of peritoneal implantation metastasis (6, 25, 26) .
EMT is a morphological change of cells or tissues that lose their epithelial characteristics and gain mesenchymal properties. EMT is the mechanism that has been well-characterized for the transition of early-stage ovarian cancers to invasive and metastatic malignancies, promoting the aggressiveness of ovarian cancers and obtaining the characteristics of stem cells after a loss of cell polarity and cell-cell adhesion (27) (28) (29) . Cells undergoing EMT exhibit loss of E-cadherin and increased N-cadherin or vimentin expression, leading to tumor cell invasion and metastasis. E-cadherin is responsible for cell-cell adhesion (30, 31) ; its loss is associated with tumor invasion, metastasis and poor prognosis (32, 33) . In addition, N-cadherin or vimentin controls tumor progression (34, 35) . There is sufficient evidence supporting the opinion that the development of EMT in ovarian cancer causes aggressive phenotypes that may promote metastasis (34) . Liu et al demonstrated that β-hCG-depleted SKOV3 cells had increased E-cadherin and decreased vimentin and N-cadherin expression (36) . In addition, Colomiere et al demonstrated that expression of mesenchyme-associated N-cadherin and vimentin was consistent with the change in fibroblast-like morphology and migratory phenotype (37) . Unsurprisingly, these results confirmed our hypothesis. In this study, we demonstrated that silencing of KDM2A suppressed the EMT process by increasing the expression level of the epithelial marker, E-cadherin, while reducing the mesenchymal markers, N-cadherin and vimentin in vitro. These data suggest that KDM2A promotes cancer cell invasion and migration via activation of EMT.
EMT is regulated by various signaling pathways, including the Wnt/β-catenin, Notch, TGF-β and PI3K/AKT signaling pathways (38) . Activation of the PI3K/AKT pathway is universal in many malignancies and is associated with carcinogenesis of all ovarian cancer subtypes (39, 40) . In this study, silencing of KDM2A downregulated levels of phospho-PI3K, phospho-AKT and phospho-mTOR, leading to inhibition of EOC progression. Furthermore, the pathway was inactivated in SKOV3 cells with the use of a PI3K inhibitor, resulting in EMT inhibition. Thus, we provide evidence that KDM2A may promote EMT through activation of the PI3K/AKT/mTOR pathway in EOC cells.
In summary, the present study demonstrated several roles of KDM2A in EOC. First, KDM2A was overexpressed in EOC and KDM2A has potential as a prognostic marker of EOC. Second, silencing of KDM2A was able to suppress proliferation, migration, invasion and EMT, as well as promote apoptosis in EOC. Additionally, we gained insight into the potential mechanism and showed that KDM2A regulated EMT and the PI3K/AKT/mTOR signaling pathway involved in metastasis. Although there were some notable discoveries in this study, many limitations still exist. One is PCR and animal experiments were not implemented. Although some researchers have confirmed changes of KDM2A expression in other tumors in vivo and in vitro (11), the results may be different. We demonstrated the effects of PI3K inhibitors in ovarian cancer, but we did not observe the consequence after the treatment of AKT and mTOR inhibitors. Despite these limitations, these results show that KDM2A may serve as a therapeutic target for clinical treatments of EOC patients. Finally, evidence suggests a correlation between EMT and the characteristics of embryonic neural cells, emphasizing the significance of the epigenetic modification enzyme enhancer (41, 42) . Thus, KDM2A could cause neural development and this behavior may be associated with tumorigenesis.
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